# Insulin Glargine (Lantus)

> Long-acting basal insulin analog for type 1 and type 2 diabetes.

Source: https://peptides.cafe/peptide/insulin-glargine
Category: Insulin Analog · Endocrine
Tag: FDA-Approved · Diabetes

## Mechanism
Recombinant human insulin analog with two arginine residues added to the B-chain and asparagine→glycine at A21, forming microprecipitates at injection site for ~24-hour glucose-lowering activity via insulin receptor activation.

## Research areas
- Type 1 diabetes basal coverage
- Type 2 diabetes basal insulin therapy
- Gestational diabetes

## Common research protocols
- Once-daily SC: Subcutaneous injection once daily at the same time, titrated to fasting glucose.

## Study summaries
- "Treat-to-target insulin glargine trials" — Diabetes Care (2003): Established efficacy and lower nocturnal hypoglycemia vs NPH insulin.

## Considerations
- FDA-approved.
- Hypoglycemia and weight gain are primary risks.
- Do not mix with other insulins.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.